Oda Naohiro, Onishi Akifumi, Mitani Reo, Tokura Takehiko, Takata Ichiro
Department of Internal Medicine, Fukuyama City Hospital, Japan.
Intern Med. 2025 Jul 1;64(13):2019-2023. doi: 10.2169/internalmedicine.4488-24. Epub 2024 Dec 5.
We herein report a 68-year-old man with advanced non-small-cell lung cancer treated with tepotinib who showed marked general edema, hypoalbuminemia, and an elevated serum creatinine level. Although tepotinib-induced kidney injury due to creatinine transporter inhibition has been reported, renal biopsy findings suggested tubulointerstitial injury due to decreased renal blood flow, likely secondary to refractory fluid retention. This case highlights the potential for true kidney injury during tepotinib therapy and underscores the importance of careful monitoring and management of adverse renal effects.
我们在此报告一名68岁患有晚期非小细胞肺癌的男性,接受了替泊替尼治疗,出现了明显的全身性水肿、低白蛋白血症和血清肌酐水平升高。虽然已有报道替泊替尼因抑制肌酐转运蛋白而导致肾损伤,但肾活检结果提示肾小管间质损伤是由于肾血流量减少所致,可能继发于难治性液体潴留。该病例凸显了替泊替尼治疗期间发生真正肾损伤的可能性,并强调了仔细监测和管理肾不良影响的重要性。